3篇
您的检索式：作者名="Jiazhen Cui"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies:a phase I clinical study显示文摘Chimeric antigen receptor(CAR)-T cell therapy against T cell malignancies faces major challenges including fratricide between CAR-T cells and product contamination from the blasts.Allogeneic CAR-T cells,generated from healthy donor T cells,can provide ready-to-use,blast-free therapeutic products,but their application could be complicated by graft-versus-host disease(GvHD)and host rejection.Here we developed healthy donor-derived,CD7-targeting CAR-T cells(RD13-01)with genetic modifications to resist fratricide,GvHD and allogeneic rejection,as well as to potentiate antitumor function.A phase I clinical trial(NCT04538599)was conducted with twelve patients recruited(eleven with T cell leukemia/lymphoma,and one with CD7-expressing acute myeloid leukemia).All patients achieved pre-set end points and eleven proceeded to efficacy evaluation.No dose-limiting toxicity,GvHD,immune effector cell-associated neurotoxicity or severe cytokine release syndrome(grade≥3)were observed.28 days post infusion,81.8%of patients(9/11)showed objective responses and the complete response rate was 63.6%(7/11,including the patient with AML).3 of the responding patients were bridged to allogeneic hematopoietic stem cell transplantation.With a median follow-up of 10.5 months,4 patients remained in complete remission.Cytomegalovirus(CMV)and/or Epstein-Barr virus(EBV)reactivation was observed in several patients,and one died from EBV-associated diffuse large B-cell lymphoma(DLBCL).Expansion of CD7-negative normal T cells was detected post infusion.In summary,we present the first report of a Phase I clinical trial using healthy donor-derived CD7-targeting allogeneic CAR-T cells to treat CD7^(+)hematological malignancies.Our results demonstrated the encouraging safety and efficacy profiles of the RD13-01 allogeneic CAR-T cells for CD7^(+)tumors. | Yongxian Hu Yali Zhou Mingming Zhang Houli Zhao Guoqing Wei Wengang Ge Qu Cui Qitian Mu Gong Chen Lu Han Tingting Guo Jiazhen Cui Xiaoyan Jiang Xiujun Zheng Shuhui Yu Xiaolong Li Xingwang Zhang Mingxi Chen Xiuju Li Ming Gao Kang Wang Cheng Zu Hao Zhang Xiaohong He Yanbin Wang Dongrui Wang Jiangtao Ren He Huang | 2022 | Cell Research2022，32，11： | 2 |
| 2 | Ginsenoside Rg1 protection against β-amyloid peptide-induced neuronal apoptosis via estrogen receptor α and glucocorticoid receptor-dependent anti-protein nitration pathway显示文摘 | Jiaying Wu Zongfu Pan Zhiqiang Wang Wenjie Zhu Yuanyuan Shen Rong Cui Jiazhen Lin Hao Yu Qiongque Wang Jianchang Qian Yongping Yu Danyan Zhu Yijia Lou | 2012 | Neuropharmacology2012，，3： | 1 |
| 3 | Nasopharyngeal Local Transcriptional Profile upon SARS-CoV-2 Omicron BA.2.2 Breakthrough Infection显示文摘The Omicron variants have continued to cause severe acute respiratory syndrome coronavirus 2 infections.To better understand the anti-viral effects of vaccination on host-virus interactions during the outbreak of BA.2.2 Omicron,we conducted RNA-seq transcriptome analysis on nasopharyngeal swabs from COVID-19 patients in Shanghai.This study was performed on selected cases from unvaccinated,fully vaccinated,and booster groups with the same founder virus infection background.We observed predominant immune cell chemotaxis and interleukin-1 production,as well as mucosal keratinization and epidermis development,in unvaccinated patients.In contrast,fully vaccinated subjects exhibited an obvious T-cell activation in the local immune response,whereas B-cell activation was higher in booster-vaccinated cases.In conclusion,our findings suggest that full or booster vaccination provides better adaptive immunity and relieve inflammation at the nasopharyngeal site,thereby reducing the risk of cytokine storm during breakthrough infection. | Yi Zhang Yang Zhou Yumeng Zhang Jiazhen Chen Jing Wu Peng Cui Shiyong Wang Yuanyuan Xu Zhongliang Shen Tao Xu Yang Li Jingwen Ai Ning Jiang Chao Qiu Wenhong Zhang | 2023 | Infectious Diseases & Immunity2023，3，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员